Client Arbor Biotechnologies Closes $73.9 Million Series C Financing

In The News
March 19, 2025
Attorneys:

Ropes & Gray represented Arbor Biotechnologies in its $73.9 million Series C financing to support the advancement of its novel gene editing therapeutics targeting diseases in the liver and central nervous system (CNS). The financing was announced in a March 18 press release.

Arbor Biotechnologies is a next-generation gene editing company based in Cambridge, Mass. 

The team was led by venture capital and emerging companies partner Brad Flint.